Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Ljunggren, Östen; Barrett, Annabel; Stoykov, Ivaylo; Langdahl, Bente L; Lems, Willem F; Walsh, J Bernard; Fahrleitner-Pammer, Astrid; Rajzbaum, Gerald; Jakob, Franz; Karras, Dimitrios; Marin, Fernando

doi:10.1186/1471-2474-14-251

Table 1 Baseline characteristics of the four subgroups and total study cohort

From: Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

	Total study cohort (n = 1581)	Group A	Group B	Group C	Group D
		Recent prior fracture^a; incident fracture (n = 119)	Recent prior fracture^a; no incident fracture (n = 646)	No recent prior fracture^a; incident fracture (n = 89)	No recent prior fracture^a; no incident fracture (n = 727)
Age (years)	71.0 (8.4)	72.1 (8.6)	71.3 (8.1)	70.6 (9.0)	70.5 (8.5)
Caucasian, %	99.2	100	99.1	100	99.1
Body Mass Index (kg/m²)	25.1 (4.3)	25.1 (4.6)	25.3 (4.2)	24.3 (4.0)	25.1 (4.3)
Early menopause (<40 years of age), %	8.9	7.9	7.9	11.9	9.6
Surgical menopause, %	18.1	20.2	15.9	23.6	19.0
Nulliparous, %	13.0	11.8	12.8	11.5	13.6
Current smoker, %	13.0	10.9	10.9	19.5	14.5
Osteoporotic hip fracture in mother, %	20.8	22.3	22.2	18.2	19.7
Time since most recent fracture (years)	2.0 (3.4)	0.3 (0.3)	0.3 (0.3)	4.5 (3.9)**	4.2 (4.1)**
Number of previous fractures after 40 years of age	2.9 (2.0)	4.0 (2.0)#	3.3 (1.9)	3.3 (2.3)	2.3 (1.9)††
Lumbar spine BMD T-score	−3.26 (1.16)	−3.26 (1.16)	−3.18 (1.22)	−3.45 (1.02)	−3.31 (1.13)
Total hip BMD T-score	−2.61 (1.05)	−2.82 (0.87)	−2.53 (1.11)	−2.79 (1.12)	−2.61 (1.00)
Back pain VAS	57.8 (26.6)	60.1 (26.5)	58.8 (26.2)	60.0 (25.2)	56.1 (27.1)
Uses arms when stands up from chair, %	63.3	70.6	65.0	*47.7‡**	62.6
Sight problems, %	45.0	54.6	43.2	52.3	44.1
>1 fall in last year, %	42.0	53.8	45.0	42.0	37.4*
Prior osteoporosis medication, %	91.8	96.6	89.6	98.9‡	92.2
Prior bisphosphonate medication, %	73.4	76.5	70.7	87.6‡#	73.6
Comorbidities, %
Rheumatoid arthritis	11.9	15.1	13.9‡	16.9	8.9
Chronic obstructive pulmonary disease	8.7	13.4	9.0	5.6	8.1
Diabetes mellitus	5.5	6.7	5.1	4.5	5.8
Concomitant medications, %
Antihypertensives	37.2	37.8	38.8	31.4	36.4
Glucocorticoids	14.8	20.2	15.4	19.8	12.8
Thyroid hormones	13.3	10.9	15.1	18.6	11.6
Benzodiazepines	12.0	16.0	11.5	16.3	11.3
Antidepressants	10.2	17.6‡	10.6	12.8	8.4

Data are presented as mean (SD) unless indicated otherwise.
^aRecent prior fracture within the last 12 months before baseline visit.
Comparisons between groups used Fisher exact tests for categorical variables, Wilcoxon signed-rank tests for time since most recent fracture and number of previous fractures, and t-tests for other continuous variables (all Bonferroni adjusted p-values).
*p < 0.05, **p < 0.001 for pairwise comparisons with groups A and B.
††p < 0.001 for pairwise comparisons with groups A, B, and C.
‡ p < 0.05 for pairwise comparison with group D.
# p < 0.05 for pairwise comparison with group B.

Back to article page